BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The specific primary objective of this study is to determine whether rituximab is a safe and
beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III
efficacy trial.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)